# VedaBio Prototype Detects Five Respiratory Targets in Under 10 Minutes at AMP 2026

> VedaBio presented proof-of-concept data at AMP 2026 showing its amplification-free CRISPR prototype returned sample-to-answer results in under 10 minutes.

- Published: 2026-11-14T17:43:38+00:00
- Section: Research & Clinical Trials
- Author: News Desk
- URL: https://newsforagent.com/news/2026-11-14/vedabio-crispr-detection-amp-2026
- Source: [Business Wire](https://www.businesswire.com/news/home/20261114935899/en/)

## Key takeaways

- VedaBio's integrated prototype achieved sample-to-answer times of under 10 minutes using target amplification-free CRISPR technology.
- The proof-of-concept study used a five-result respiratory panel with automated nucleic acid extraction.
- Chief Scientific Officer Brett Robb presented the findings as poster TT061 at the AMP 2026 Annual Meeting in Seattle.

VedaBio presented proof-of-concept data at the Association for Molecular Pathology 2026 Annual Meeting showing sample-to-answer times of under 10 minutes with its integrated, target amplification-free CRISPR-based molecular diagnostics technology. The San Diego company announced the findings in a [Business Wire](https://www.businesswire.com/news/home/20261114935899/en/) release on November 14, 2026.

## VedaBio's Five-Result Respiratory Panel Prototype

In a proof-of-concept study using a five-result respiratory panel, [VedaBio](https://akta.pro/company-profiles/00002hg/vedabio)'s integrated prototype achieved rapid, multiplex molecular detection in a workflow that included automated nucleic acid extraction. The company said its target amplification-free CRISPR technology is designed to reduce the time and complexity associated with conventional molecular testing methods, supporting potential use in urgent care and other decentralized settings.

VedaBio is developing its platform around five pillars: speed, simplicity, breadth, accuracy and economics. The company said the findings highlight progress toward combining rapid, multiplex detection with a streamlined testing workflow.

"Molecular diagnostics should not have to come with trade-offs between speed, complexity and performance," said Brett Robb, PhD, Chief Scientific Officer of VedaBio. "Our goal is to challenge those limitations and bring the benefits of molecular testing closer to patients."

Robb presented the work as poster TT061, titled "Target-Amplification-Free CRISPR-Cas Nucleic Acid Detection with OR-Logic Multiplexing Enables Clinically Relevant, Rapid Point-of-Care Testing," in a session on November 14, 2026, from 9:15 to 10:15 a.m. Pacific Time.

## VedaBio's Funding and Siemens Agreement

According to akta.pro [company records](https://akta.pro/company-data), VedaBio's September 2025 Series A extension and strategic agreement with Siemens Healthineers totaled up to $25 million to validate amplification-free CRISPR Cascade technology and accelerate decentralized diagnostic product development. The same records show initial funding of over $40 million raised at launch in October 2023, backed by lead investor OMX Ventures and family offices including Kleinmuntz Associates, for total funding of $65 million. VedaBio was founded in 2023 and is pre-revenue, with a headcount range of 11 to 50.

## VedaBio's Urgent Care Partnership Before AMP

In September 2026, VedaBio announced a partnership with UCP Merchant Medicine to prepare urgent care clinics for its platform, the San Diego Business Journal reported. Earlier that month, VedaBio selected UCP Merchant Medicine for a multi-year engagement to establish benchmarks, training and pricing ahead of an anticipated FDA clearance, according to Business Wire Blog. VedaBio also appointed Valerie Dixon, CFO of Cleveland Diagnostics, as its first independent board member in September 2026, Business Wire Blog reported.

## What Comes Next for VedaBio

The UCP Merchant Medicine engagement is intended to establish benchmarks, training and pricing ahead of an anticipated FDA clearance, according to Business Wire Blog. VedaBio's platform is described on its [company website](https://vedabio.com) as designed to detect targets without the amplification step required by conventional methods.

## Companies in this story

- [VedaBio company profile](https://akta.pro/company-profiles/00002hg/vedabio) · website: https://vedabio.com

---
News for Agent · https://newsforagent.com/llms.txt